- Home
- AIRS vs GOSS Comparison
AIRS vs GOSS Comparison
Compare AIRS & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRS
- GOSS
- Stock Information
- Founded
- AIRS 2012
- GOSS 2015
- Country
- AIRS United States
- GOSS United States
- Employees
- AIRS N/A
- GOSS N/A
- Industry
- AIRS Medical/Nursing Services
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- AIRS Health Care
- GOSS Health Care
- Exchange
- AIRS Nasdaq
- GOSS Nasdaq
- Market Cap
- AIRS 249.9M
- GOSS 246.6M
- IPO Year
- AIRS 2021
- GOSS 2019
- Fundamental
- Price
- AIRS $4.95
- GOSS $1.07
- Analyst Decision
- AIRS Hold
- GOSS Strong Buy
- Analyst Count
- AIRS 2
- GOSS 5
- Target Price
- AIRS $5.50
- GOSS $9.20
- AVG Volume (30 Days)
- AIRS 111.4K
- GOSS 989.6K
- Earning Date
- AIRS 11-07-2024
- GOSS 11-07-2024
- Dividend Yield
- AIRS N/A
- GOSS N/A
- EPS Growth
- AIRS N/A
- GOSS N/A
- EPS
- AIRS N/A
- GOSS N/A
- Revenue
- AIRS $193,025,000.00
- GOSS $95,842,000.00
- Revenue This Year
- AIRS N/A
- GOSS N/A
- Revenue Next Year
- AIRS $11.85
- GOSS N/A
- P/E Ratio
- AIRS N/A
- GOSS N/A
- Revenue Growth
- AIRS 6.58
- GOSS N/A
- 52 Week Low
- AIRS $2.92
- GOSS $0.45
- 52 Week High
- AIRS $8.30
- GOSS $1.60
- Technical
- Relative Strength Index (RSI)
- AIRS 54.52
- GOSS 62.64
- Support Level
- AIRS $4.36
- GOSS $0.98
- Resistance Level
- AIRS $5.95
- GOSS $1.07
- Average True Range (ATR)
- AIRS 0.52
- GOSS 0.07
- MACD
- AIRS -0.02
- GOSS 0.01
- Stochastic Oscillator
- AIRS 45.57
- GOSS 83.26
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. At Elite Body Sculpture, company provide custom body contouring using proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.